Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply

Lancet Neurol. 2020 Sep;19(9):716-717. doi: 10.1016/S1474-4422(20)30281-7.

Authors

Masayuki Tahara¹, Tomoko Oeda², Hideyuki Sawada²

Affiliations

¹ Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan. Electronic address: tahara.masayuki.ne@mail.hosp.go.jp.
² Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan.

PMID: 32822625
DOI: 10.1016/S1474-4422(20)30281-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Double-Blind Method
Humans
Neuromyelitis Optica*
Recurrence
Rituximab

Substances

Rituximab